‘Why is survival with triple negative breast cancer so low? insights and talking points from preclinical and clinical research’

References

• Pareja F, Geyer FC, Marchiò C, et al. Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. NPJ Breast Cancer. 2016 Nov 16 2(1):16036.
   PubMedGoogle Scholar
• Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938–1948.
   PubMed Web of Science ®Google Scholar
• Howard FM, Olopade OI. Epidemiology of Triple-Negative Breast Cancer: a Review. Cancer J. 2021 Jan-Feb 01;27(1):8–16’.
   PubMed Web of Science ®Google Scholar
• Weigelt B, Reis Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol. 2009;6:718.
   PubMed Web of Science ®Google Scholar
• Brouckaert O, Wildiers H, Floris G, et al. Update on triple-negative breast cancer: prognosis and management strategies. Int J Womens Health. 2012;4:511–520.
   PubMedGoogle Scholar
• Geyer FC, Pareja F, Weigelt B, et al. The Spectrum of Triple-Negative Breast Disease: high- and Low-Grade Lesions. Am J Pathol. 2017;187(10):2139–2151. t.
   PubMed Web of Science ®Google Scholar
• Jung SY, Kim HY, Nam BH, et al. Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer. Breast Cancer Res Treat. 2010 Apr;120(3):627–637.
   PubMed Web of Science ®Google Scholar
• Van Hoeven KH, Drudis T, Cranor ML, et al. Low-grade adenosquamous carcinoma of the breast. A clinocopathologic study of 32 cases with ultrastructural analysis. Am J Surg Pathol. 1993 Mar;17(3):248–258.
   PubMed Web of Science ®Google Scholar
• Prat A, Parker JS, Karginova O, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12:R68.
   PubMed Web of Science ®Google Scholar
• Fougner C, Bergholtz H, Norum JH, et al. T. Re-definition of claudin-low as a breast cancer phenotype. Nature Communications. 2020;11(1):1787.
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011 Jul;121(7):2750–2767.
   PubMed Web of Science ®Google Scholar
• Marchiò C, Weigelt B, Reis-Filho JS. Adenoid cystic carcinomas of the breast and salivary glands (or “The strange case of Dr Jekyll and Mr Hyde” of exocrine gland carcinomas). J Clin Pathol. 2010 Mar;63(3):220–228.
   PubMed Web of Science ®Google Scholar
• Lozada JR, Basili T, Pareja F, et al. Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms (solid papillary carcinomas with reverse polarity) harbour recurrent mutations affecting IDH2 and PIK3CA: a validation cohort. Histopathology. 2018 Aug;73(2):339–344.
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Jovanovic B, Chen X, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLOS ONE. 2016;11:0157368.
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 2014;232(2):142–150.
   PubMed Web of Science ®Google Scholar
• Rakha E, Reis-Filho JS. Basal-like breast carcinoma: from expression profiling to routine practice. Arch Pathol Lab Med. 2009 Jun;133(6):860–868.
   PubMed Web of Science ®Google Scholar
• Rakha EA, Elsheikh SE, Aleskandarany MA, et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res. 2009;15:2302–2310.
   PubMed Web of Science ®Google Scholar
• Hayes MJ, Thomas D, Emmons A, et al. Genetic changes of Wnt pathway genes are common events in metaplastic carcinomas of the breast. Clin Cancer Res. 2008;14(13):4038–4044.
   PubMed Web of Science ®Google Scholar
• Bareche Y, Venet D, Ignatiadis M, et al. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis. Ann Oncol. 2018;29:895–902.
   PubMed Web of Science ®Google Scholar
• Prat A, Pineda E, Adamo B, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015;24(Suppl 2):S26–35.
   PubMedGoogle Scholar
• Burstein MD, Tsimelzon A, Poage GM, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015;21(7):1688–1698.
   PubMed Web of Science ®Google Scholar
• Liu YR, Jiang YZ, Xu XE, et al. Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer. Breast Cancer Res. 2016;18(1):33.
   PubMedGoogle Scholar
• Shepherd JH, Ballman K, Polley MYC, et al. Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. J clin oncol. 2022 Apr;40(12):1323–1334.
   PubMed Web of Science ®Google Scholar
• Tutt A, Tovey H, Cheang MCU, et al. Carboplatin in BRCA1/2–mutated and triple-negative breast cancer BRCAness subgroups: the TNT trial. Nat Med. 2018;24(5):628–637.
   PubMed Web of Science ®Google Scholar
• Sukumar J, Gast K, Quirogaa D, et al. Triple-negative breast cancer: promising prognostic biomarkers currently in development. Expert Rev Anticancer Ther. 2021;21(2):135–148.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Conchas GA, Rodriguez-Romo L, Hernandez-Barajas D, et al. Epidermal growth factor receptor overexpression and outcomes in early breast cancer: a systematic review and a meta-analysis. Cancer Treat Rev. 2018;62:1–8.
   PubMed Web of Science ®Google Scholar
• Bernsdorf M, Ingvar C, Jörgensen L, et al. Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial. Breast Cancer Res Treat. 2011;126(2):463–470.
   PubMed Web of Science ®Google Scholar
• Matsuda N, Wang X, Lim B, et al. Safety and efficacy of panitumumab plus neoadjuvant chemotherapy in patients with primary HER2-negative inflammatory breast cancer. JAMA Oncol. 2018;4(9):1207–1213.
   PubMed Web of Science ®Google Scholar
• Schuler M, Awada A, Harter P, et al. A phase II trial to assess efficacy and safety of Afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat. 2012;134(3):1149–1159.
   PubMed Web of Science ®Google Scholar
• Carey LA, Rugo HS, Marcom PK, et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. 2012;30(21):2615–2623.
   PubMed Web of Science ®Google Scholar
• Yardley DA, Ward PJ, Daniel BR, et al. Panitumumab, gemcitabine, and carboplatin as treatment for women with metastatic triple-negative breast cancer: a Sarah Cannon Research Institute phase II trial. Clin Breast Cancer. 2016;16(5):349–355.
   PubMed Web of Science ®Google Scholar
• Albanell J, Ruiz A, Lluch A, et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol. 2019 Aug 10;23(23):5323–5333.
   Google Scholar
• Linderholm BK, Hellborg H, Johansson U, et al. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol. 2009;20(10):1639–1646.
   PubMed Web of Science ®Google Scholar
• El-Arab LRE, Swellam M, El Mahdy MM. Metronomic chemotherapy in metastatic breast cancer: impact on VEGF. J Egypt Natl Cancer Inst. 2012;24(1):15–22.
   PubMedGoogle Scholar
• Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666–2676.
   PubMed Web of Science ®Google Scholar
• Brufsky AM, Hurvitz S, Perez E, et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2011;29(32):4286–4293.
   PubMed Web of Science ®Google Scholar
• Von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med. 2012;366(4):299–309.
   PubMed Web of Science ®Google Scholar
• Miller KD, O’Neill A, Gradishar W, et al. Double-blind phase III trial of adjuvant chemotherapy with and without bevacizumab in patients with lymph node-positive and high-risk lymph node-negative breast cancer (E5103. J Clin Oncol. 2018;36(25):2621–2629.
   PubMed Web of Science ®Google Scholar
• Wang RX, Chen S, Huang L, et al. Monitoring Serum VEGF in neoadjuvant chemotherapy for patients with triple-negative breast cancer: a new strategy for early prediction of treatment response and patient survival the oncologist. Oncologist. 2019 Jun;24(6):753–761.
   Google Scholar
• Perez-Garcia J, Muñoz-Couselo E, Soberino J, et al. Targeting FGFR pathway in breast cancer. Breast. 2018;37:126–133.
   PubMed Web of Science ®Google Scholar
• Jafarian AH, Kooshkiforooshani M, Farzad F, et al. The relationship between fibroblastic growth factor receptor-1 (FGFR1) gene amplification in triple negative breast carcinomas and clinicopathological prognostic factors. Iran J Pathol. 2019;14(4):299–304.
   PubMedGoogle Scholar
• Tomiguchi M, Yamamoto Y, Yamamoto-Ibusuki M, et al. Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive/human epidermal growth factor receptor-2-negative primary breast cancer. Cancer Sci. 2016;107(4):491–498.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Seo AN, Park SY, et al. Low prognostic implication of fibroblast growth factor family activation in triple-negative breast cancer subsets. Ann Surg Oncol. 2014;21(5):1561–1568.
   PubMed Web of Science ®Google Scholar
• Sun S, Jiang Y, Zhang G, et al. Increased expression of fibroblastic growth factor receptor 2 is correlated with poor prognosis in patients with breast cancer. J Surg Oncol. 2012;105(8):773–779.
   PubMed Web of Science ®Google Scholar
• Tarantino P, Hamilton E, Tolaney SM, et al. HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol. 2020;38(17):1951–1962.
   PubMed Web of Science ®Google Scholar
• Broner E, Alpert G, Gluschnaider U. Abstract AL101: mediated tumor inhibition in notch-altered TNBC PDX models. J clin oncol. 2019;37(15):1064.
   Web of Science ®Google Scholar
• Hossain F, Majumder S, Ucar DA, et al. Notch signaling in myeloid cells as a regulator of tumor immune responses. Front Immunol. 2018;9:1288.
   PubMed Web of Science ®Google Scholar
• Speiser JJ, Ersahin C, Osipo C. The functional role of Notch signaling in triple-negative breast cancer. Vitam Horm. 2013;93:277–306.
   PubMed Web of Science ®Google Scholar
• Jansson S, Bendahl P-O, Grabau DA, et al. The three receptor tyrosine kinases c-kit, vegfr2 and pdgfra, closely spaced at 4q12, show increased protein expression in triple-negative breast cancer. PLoS ONE. 2014 Jul 15;9(7):e102176.
   Web of Science ®Google Scholar
• Thike AA, Iqbal J, Cheok PY, et al. Triple Negative Breast Cancer: outcome Correlation With Immunohistochemical Detection of Basal Markers. Am J Surg Pathol. 2010 Jul;34(7):956–964.
   Google Scholar
• Luo Y, Huang W, Zhang H, et al. Prognostic significance of CD117 expression and TP53 missense mutations in triple-negative breast cancer. Oncol Lett. 2018 May;15(5):6161–6170.
   Google Scholar
• Ellis H, Ma CX. PI3K inhibitors in breast cancer therapy. Curr Oncol Rep. 2019;21(12):110.
   PubMed Web of Science ®Google Scholar
• Wang DY, Gendoo DMA, Ben-David Y, et al. A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling. Breast Cancer Res. [2019 Jan 31];21(1):18.
   PubMedGoogle Scholar
• Khramtsov AI, Khramtsova GF, Tretiakova M, et al. Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol. 2010;176(6):2911–2920.
   PubMed Web of Science ®Google Scholar
• Thakur R, Trivedi R, Rastogi N, et al. Inhibition of STAT3, FAK and Src mediated signaling reduces cancer stem cell load, tumorigenic potential and metastasis in breast cancer, Sci. Rep. 2015;5:10194.
   Google Scholar
• Butti R, Das S, Gunasekaran VP, et al. Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges. Mol Cancer. 2018;17(1):1–18.
   PubMedGoogle Scholar
• Robertson H, Hayes JD, Sutherland C. A partnership with the proteasome; the destructive nature of GSK3. Biochem Pharmacol. 2018;147:77–92.
   PubMed Web of Science ®Google Scholar
• Moradi-Kalbolandi S, Hosseinzade A, Salehi M, et al. Monoclonal antibody-based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER. J Pharm Pharmacol. 2018;70(7):841–854.
   PubMed Web of Science ®Google Scholar
• Giovannelli P, Di Donato M, Auricchio F, et al. Androgens induce invasiveness of triple negative breast cancer cells through ar/src/pi3-k complex assembly. Sci Rep. [2019 Mar 14];9(1):4490.
   PubMedGoogle Scholar
• Santonja A, Sánchez-Muñoz A, Lluch A, et al. Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy. Oncotarget. 2018;9(41):26406–26416.
   PubMedGoogle Scholar
• Dieci MV, Tsvetkova V, Griguolo G, et al. Androgen receptor expression and association with distant disease-free survival in triple negative breast cancer: analysis of 263 patients treated with standard therapy for stage i-iii disease. Front Oncol. 2019 Jun 6;9:452.
   PubMed Web of Science ®Google Scholar
• Wang C, Pan B, Zhu H, et al. Prognostic value of androgen receptor in triple negative breast cancer: a meta-analysis. Oncotarget. 2016;7(29):46482–46491.
   PubMedGoogle Scholar
• Qu Q, Mao Y, Fei XC, et al. The impact of androgen receptor expression on breast cancer survival: a retrospective study and meta-analysis. PLoS One. 2013;8(12):e82650.
   PubMed Web of Science ®Google Scholar
• Sharma P, Klemp JR, Kimler BF, et al. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Res Treat. 2014;145(3):707–714.
   PubMed Web of Science ®Google Scholar
• Telli ML, Timms KM, Reid J, et al. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Clin Cancer Res. 2016;22(15):3764–3773.
   PubMed Web of Science ®Google Scholar
• Copson ER, Maishman TC, Tapper WJ, et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol. 2018;19(2):169–180.
   PubMed Web of Science ®Google Scholar
• Liu M, Xie F, Liu M, et al. Association between BRCA mutational status and survival in patients with breast cancer: a systematic review and meta analysis. Breast Cancer Res Treat. 2021;186:591–605.
   PubMed Web of Science ®Google Scholar
• Nicolai J, Birkbak Z, C, et al. Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents. Cancer Discov. 2012 Apr;2(4):366–375.
   PubMed Web of Science ®Google Scholar
• Popova T, Manie E, Rieunier G, et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with brca1/2 inactivation. Cancer Res. 2012;72(21):5454–5462.
   PubMed Web of Science ®Google Scholar
• Abkevich V, Timms KM, Hennessy BT, et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer. 2012 Nov;107(10):1776–1782.
   PubMed Web of Science ®Google Scholar
• Telli M, Hellyer J, Audeh W, et al. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer. Breast Cancer Res Treat. 2018 Apr;168(3):625–630.
   PubMed Web of Science ®Google Scholar
• Lin PH, Chen M, Tsai LW, et al. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer. Cancer Sci. 2020;111(4):1375–1384.
   PubMed Web of Science ®Google Scholar
• Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer. 2016;16(2):110–120.
   PubMed Web of Science ®Google Scholar
• Duffy MJ, Synnott NC, Crown J. Mutant p53 in breast cancer: potential as a therapeutic target and biomarker. Breast Cancer Res Treat. 2018;170(2):213–219.
   PubMed Web of Science ®Google Scholar
• Turner N, Moretti E, Siclari O, et al. Cancer Treatme nt Revie ws Targeting triple negative breast cancer: is p53 the answer? Cancer Treat Rev. 2013;39(5):541–550.
   PubMed Web of Science ®Google Scholar
• Ghosh M, Saha S, Bettke J, et al. Mutant p53 suppresses innate immune signaling to promote tumorigenesis. Cancer Cell. 2021;39:494–508.e5.
   PubMed Web of Science ®Google Scholar
• Synnott NC, Murray A, McGowan PM, et al. Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer? Int J Cancer. 2017;140(1):234–246.
   PubMed Web of Science ®Google Scholar
• Heyza JR, Lei W, Watz D, et al. Identification and characterization of synthetic viability with ERCC1 deficiency in response to interstrand crosslinks in lung cancer. Clin Cancer Res. 2019;25:2523–2536.
   PubMed Web of Science ®Google Scholar
• Nakagawa M, Bando Y, Nagao T, et al. Expression of p53, Ki-67, E-cadherin, N-cadherin and TOP2A in triple-negative breast cancer. Anticancer Res. 2011;31(6):2389–2393.
   PubMed Web of Science ®Google Scholar
• Wang W, Wu J, Zhang P, et al. Prognostic and predictive value of Ki-67 in triple-negative breast cancer. Oncotarget. 2016 May 24;7(21):31079–87.
   Google Scholar
• Ilie SM, Bacinschi XE, Botnariuc I, et al. Potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis. Breast Cancer (Dove Med Press). 2018 Nov 23;10:177–194.
   Google Scholar
• Paszek S, Gablo N, Barnas E, et al. Dysregulation of microRNAs in triple-negative breast cancer. Ginekol Pol. 2017;88(10):530–536.
   PubMed Web of Science ®Google Scholar
• Malla RR, Kumari S, Gavara MM, et al. A perspective on the diagnostics, prognostics, and therapeutics of microRNAs of triple-negative breast cancer. Biophys Rev. 2019;11(2):227–234.
   PubMedGoogle Scholar
• Adams BD, Wali VB, Cheng CJ, et al. miR-34a silences c-SRC to attenuate tumor growth in triple-negative breast cancer. Cancer Res. 2016;76(4):927–939.
   PubMed Web of Science ®Google Scholar
• Augoff K, McCue B, Plow EF, et al. MiR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer. Mol Cancer. 2012 Jan 30;11:5.
   PubMed Web of Science ®Google Scholar
• Sakthianandeswaren A, Liu S, Sieber O. Long noncoding RNA LINP1: scaffolding nonhomologous end joining. Cell Death Discov. 2016 Jul 18;2:16059.
   PubMed Web of Science ®Google Scholar
• Eades G, Wolfson B, Zhang Y, et al. lincRNA-RoR and miR-145 Regulate Invasion in Triple-Negative Breast Cancer via Targeting ARF6. Mol Cancer Res. 2015 Feb;13(2):330–8.
   PubMed Web of Science ®Google Scholar
• Shi F, Xiao F, Ding P, et al. Long Noncoding RNA Highly Up-regulated in Liver Cancer Predicts Unfavorable Outcome and Regulates Metastasis by MMPs in Triple-negative Breast Cancer. Arch Med Res. 2016 Aug;47(6):446–453.
   Web of Science ®Google Scholar
• Wagner J, Rapsomaniki MA, Chevrier S, et al. A single-cell atlas of the tumor and immune ecosystem of human breast cancer. Cell. 2019;177(5):1330.
   PubMed Web of Science ®Google Scholar
• Desmedt C, Haibe-Kains B, Wirapati P, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res. 2008;14(16):5158–5165.
   PubMed Web of Science ®Google Scholar
• Sabatier R, Finetti P, Mamessier E, et al. Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget. 2015;6(7):5449–5464.
   PubMedGoogle Scholar
• Cerbelli B, Pernazza A, Botticelli A, et al. PD-L1 expression in TNBC: a predictive biomarker of response to neoadjuvant chemotherapy? Biomed Res Int. 2017;2017:1750925.
   PubMed Web of Science ®Google Scholar
• Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108–2121.
   PubMed Web of Science ®Google Scholar
• Deng L, Lu D, Bai Y, et al. Immune Profiles of Tumor Microenvironment and Clinical Prognosis among Women with Triple-Negative Breast Cancer. Cancer Epidemiol Biomarkers Prev. 2019 Dec;28(12):1977–1985.
   PubMed Web of Science ®Google Scholar
• Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase iii randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based Chemotherapy: BIG 02-98. J clin oncol. 2013 Mar;31(7):860–867.
   PubMed Web of Science ®Google Scholar
• Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40–50.
   PubMed Web of Science ®Google Scholar
• Mao Y, Qu Q, Zhang Y, et al. The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. PLoS ONE. 2014;9(12):1–21.
   Web of Science ®Google Scholar
• V DM, Criscitiello C, Goubar A, et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol. 2014;25(3):611–618.
   PubMed Web of Science ®Google Scholar
• Craven KE, Gökmen-Polar Y, Badve SS. CIBERSORT analysis of TCGA and METABRIC identifies subgroups with better outcomes in triple negative breast cancer. Sci Rep. 2021 Dec;11(1):4691.
   PubMed Web of Science ®Google Scholar
• Karn T, Jiang T, Hatzis C, et al. Association between genomic metrics and immune infiltration in triple-negative breast cancer. JAMA Oncol. 2017 Dec;3(12):1707.
   PubMed Web of Science ®Google Scholar
• Alva AS, Mangat PK, Garrett-Mayer E, et al. Pembrolizumab in patients with metastatic breast cancer with high tumor mutational burden: results from the targeted agent and profiling utilization registry (TAPUR) study. J clin oncol. 2021 Aug;39(22):2443–2451.
   PubMed Web of Science ®Google Scholar
• Otranto M, Sarrazy V, Bonte F, et al. The role of the myofibroblast in tumor stroma remodeling. Cell Adh Migr. 2012;6(3):203–219.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
   PubMed Web of Science ®Google Scholar
• Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep. 2014;15(12):1243–1253.
   PubMed Web of Science ®Google Scholar
• Sormendi S, Wielockx B. Hypoxia pathway proteins as central mediators of metabolism in the tumor cells and their microenvironment. Frontiers in Immunology. 2018;9:40.
   PubMed Web of Science ®Google Scholar
• Yang X, Weng X, Yang Y, et al. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer. AGING (Albany NY). 2021 Aug 2;13(15):19486–19509.
   Google Scholar
• Cosse JP, Michiels C. Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anticancer Agents Med Chem. 2008;8:790–797.
   PubMed Web of Science ®Google Scholar
• Bhola NE, Balko JM, Dugger TC, et al. TGF-beta inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Invest. 2013;123:1348–1358.
   PubMed Web of Science ®Google Scholar
• Jung HY, Fattet L, Yang J. Molecular pathways: linking tumor microenvironment to epithelial-mesenchymal transition in metastasis, Clin. Cancer Res. 2015;21(5):962–968.
   Web of Science ®Google Scholar
• Morel AP, Lievre M, Thomas C, et al. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLOS One. 2008;3(8):e2888.
   PubMed Web of Science ®Google Scholar
• Tsai MJ, Chang WA, Huang MS, et al. Tumor microenvironment: a new treatment target for cancer. ISRN Biochem. 2014 Apr 10;2014:351959.
   PubMedGoogle Scholar
• Helfen A, Roth J, Ng T, et al. In vivo imaging of Pro- and antitumoral cellular components of the tumor microenvironment. J Nucl Med. 2018;59(2):183–188.
   PubMed Web of Science ®Google Scholar
• Darvin P, Toor SM, Nair VS, et al. Immune checkpoint inhibitors: recent progress and potential biomarkers, Exp. Mol Med. 2018;50(12):165.
   Google Scholar
• Szekely B, BossuyT V, Li X, et al. Immunological differences between primary and metastatic breast cancer. Ann Oncol. 2018;29:2232–2239.
   PubMed Web of Science ®Google Scholar
• Holl EK, Frazier VN, Landa K, et al. Examining peripheral and tumor cellular immunome in patients with cancer. Front Immunol. 2019;10:1767.
   PubMed Web of Science ®Google Scholar
• Gruosso T, Gigoux M, Manem SFK, et al. Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. J Clin Investig. 2019 Mar;129(4):1785–1800.
   PubMed Web of Science ®Google Scholar
• Yam C, Yen Yen E, Jeffrey T, et al. Immune phenotype and response to neoadjuvant therapy in triple-negative breast cancer. Clin Cancer Res. 2021 Oct 1;27(19):5365–5375.
   PubMed Web of Science ®Google Scholar
• Bianchini G, Wang WQ, Danenberg E, et al. Abstract GS1-00: single-cell spatial analysis by imaging mass cytometry and immunotherapy response in triple-negative breast cancer (TNBC) in the NeoTRIPaPDL1 trial. Cancer Res. 2022 Feb;82(4_Supplement):GS1-00-GS1–00.
   Google Scholar
• O’Reilly EA, Gubbins L, Sharma S, et al. The fate of chemoresistance in triple negative breast cancer (TNBC), BBA Clin. 2015 Mar 12;3:257–275.
   Google Scholar
• Das M, Law S. Role of tumor microenvironment in cancer stem cell chemoresistance and recurrence. Int J Biochem Cell Biol. 2018;103:115–124.
   PubMed Web of Science ®Google Scholar
• Bianchini G, Balko JM, Mayer IA, et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13:674–690.
   PubMed Web of Science ®Google Scholar
• Berry DA, PhD C, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006 Apr 12;295(14):1658.
   PubMed Web of Science ®Google Scholar
• Couch FJ, Hart SN, Sharma P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. 2015;33(4):304–311.
   PubMed Web of Science ®Google Scholar
• Poggio F, Bruzzone M, Ceppi M, et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol. [2018 Jul 1];29(7):1497–1508.
   PubMed Web of Science ®Google Scholar
• Yu K, Ye F, He M, et al. Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2020;6(9):1390–1396.
   PubMed Web of Science ®Google Scholar
• Diéras V, Han HS, Kaufman B, et al. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 Oct;21(10):1269–1282.
   PubMed Web of Science ®Google Scholar
• Pandy JGP, Balolong-Garcia JC, Cruz-Ordinario MVB, et al. Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review. BMC Cancer. [2019 Nov 8];19(1):1065.
   PubMed Web of Science ®Google Scholar
• Masuda N, Lee SJ, Ohtani S, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med. [2017 Jun 1];376(22):2147–2159.
   PubMed Web of Science ®Google Scholar
• Wang X, Wang S, Huang H, et al. Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the sysucc-001 randomized clinical trial. JAMA. 2021;325(1):50–58.
   PubMed Web of Science ®Google Scholar
• van Mackelenbergh Mt, Seither F, Möbus V, et al. Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients. Eur J Cancer. 2022;166:185–201’.
   PubMedGoogle Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet. 2019;393:1440–1452.
   PubMed Web of Science ®Google Scholar
• Loibl S, Untch M, Burchardi N, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019 Aug;30(8):1279–1288.
   PubMed Web of Science ®Google Scholar
• Schmid P, Cortes J, Dent R, et al. KEYNOTE-522: phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC). Ann Oncol. 2019;30:v853–v854.
   PubMedGoogle Scholar
• Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020 Oct 10; 396(10257):1090–1100.
   PubMed Web of Science ®Google Scholar
• Nanda R, Liu MC, Yau C, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer. JAMA Oncol. 2020 May;6(5):676.
   PubMed Web of Science ®Google Scholar
• Nedeljkovic M, Damjanovic A. Mechanisms of chemotherapy resistance in triple-negative breast cancer-how we can rise to the challenge. Cells. 2019 Aug 22;8(9):957.
   PubMed Web of Science ®Google Scholar
• Marra A, Trapani D, Viale G, et al. Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. NPJ Breast Cancer. 2020 Oct 16;6:54.
   PubMed Web of Science ®Google Scholar
• Sissung TM, Baum CE, Kirkland CT, et al. Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol. 2010;44:152–167.
   PubMed Web of Science ®Google Scholar
• Yamada A, Ishikawa T, Ota I, et al. High expression of ATP-binding cassette transporter ABCC11 in breast tumors is associated with aggressive subtypes and low disease-free survival. Breast Cancer Res Treat. 2013;137:773–782.
   PubMed Web of Science ®Google Scholar
• L X, Zhao Z, Wang K, et al. Expression of aldehyde dehydrogenase 1 and ATP-binding cassette superfamily G member 2 is enhanced in primary foci and metastatic lymph node from patients with triple-negative breast cancer. Biomed. Res. 2017;28(11):5078–5083.
   Google Scholar
• Guestini F, Ono K, Miyashita M, et al. Impact of Topoisomerase IIa, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat. 2019;173:275–288.
   PubMed Web of Science ®Google Scholar
• Das S, Samant RS, Shevde LA. Nonclassical activation of Hedgehog signaling enhances multidrug resistance and makes cancer cells refractory to Smoothened-targeting Hedgehog inhibition. J Biol Chem. 2013;288:11824–11833.
   PubMed Web of Science ®Google Scholar
• Britton KM, Eyre R, Harvey IJ, et al. Breast cancer, side population cells and ABCG2 expression. Cancer Lett. 2012;323:97–105.
   PubMed Web of Science ®Google Scholar
• Arumugam A, Subramani R, Nandy SB, et al. Silencing growth hormone receptor inhibits estrogen receptor negative breast cancer through ATP-binding cassette sub-family G member 2. Exp Mol Med. 2019;51:2.
   PubMed Web of Science ®Google Scholar
• Oguri T, Bessho Y, Achiwa H, et al. MRP8/ABCC11 directly confers resistance to 5-fluorouracil. Mol. Cancer Ther. 2007;6:122–27’.
   Google Scholar
• O’Connor R, O’Leary M, Ballot J, et al. A phase I clinical and pharmacokinetic study of the multi- drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer. Cancer Chemother. Pharm. 2007 Jan;59(1):79–87.
   Google Scholar
• Peng H, Dong Z, Qi J, et al. A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy. PLoS ONE. 2009;4:e5676.
   PubMed Web of Science ®Google Scholar
• Wu S, Fu L. Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells. Mol Cancer. 2018;17:25.
   PubMed Web of Science ®Google Scholar
• Wang S, Tan X, Li S, et al. Indomethacin-based stimuli-responsive micelles combined with paclitaxel to overcome multidrug resistance. Oncotarget. 2017;8:111281–111294.
   PubMedGoogle Scholar
• Creighton CJ, Li X, Landis M, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA. 2009;106:13820–13825.
   PubMed Web of Science ®Google Scholar
• Lee HE, Kim JH, Kim YJ, et al. An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. Br J Cancer. 2011;104:1730–1738.
   PubMed Web of Science ®Google Scholar
• Park SY, Lee HE, Li H, et al. Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res. 2010;16:876–887.
   PubMed Web of Science ®Google Scholar
• Ma F, Li H, Wang H, et al. Enriched CD44(+)/CD24(-) population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC. Cancer Lett. 2014;353:153–159.
   PubMed Web of Science ®Google Scholar
• Shibata M, Hoque MO. Targeting cancer stem cells: a strategy for effective eradication of cancer. Cancers (Basel). 2019 May 27;11(5):732.
   PubMed Web of Science ®Google Scholar
• Zhou S, Schuetz JD, Bunting KD, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med. 2001;7:1028–1034.
   PubMed Web of Science ®Google Scholar
• Yang C, He Y, Zhang H, et al. Selective killing of breast cancer cells expressing activated CD44 using CD44 ligand-coated nanoparticles in vitro and in vivo. Oncotarget. 2015 Jun 20;6(17):15283–96.
   Google Scholar
• He L, Gu J, Lim LY, et al. Nanomedicine-mediated therapies to target breast cancer stem cells. Front Pharmacol. 2016;7:1–13.
   PubMed Web of Science ®Google Scholar
• Shishido Y, Ueno S, Yamazaki R, et al. ABCG2 inhibitor YHO-13351 sensitizes cancer stem/Initiating-like side population cells to irinotecan. Anticancer Res. 2013;33:1379–1386.
   PubMed Web of Science ®Google Scholar
• Friboulet L, Soria JC, Olaussen KA. The “Guardian of the Genome”-An Old Key to Unlock the ERCC1 Issue. Clin Cancer Res. 2019;25:2369–2371.
   PubMed Web of Science ®Google Scholar
• Isakoff SJ, Mayer EL, He L, et al. TBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. J Clin Oncol. 2015;33:1902–1909.
   PubMed Web of Science ®Google Scholar
• Bae SY, Nam SJ, Jung Y, et al. Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer. Breast Cancer Res Treat. 2018;172:437–444.
   PubMed Web of Science ®Google Scholar
• Kim JM, Chen DS. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann Oncol. 2016;27(8):1492–1504.
   PubMed Web of Science ®Google Scholar
• Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res. 2013;19(5):1021–1034.
   PubMed Web of Science ®Google Scholar
• Adams S, Loi S, Toppmeyer D, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30:405–411.
   PubMed Web of Science ®Google Scholar
• Adams S, Schmid P, Rugo HS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30:397–404.
   PubMed Web of Science ®Google Scholar
• Bian L, Zhang H, Wang T, et al. JS001, an anti-PD-1 mAb for advanced triple negative breast cancer patients after multi-line systemic therapy in a phase I trial. Ann. Transl. Med. 2019;7. 435.
   PubMed Web of Science ®Google Scholar
• Dirix LY, Takacs I, Jerusalem G, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res Treat. 2018;167:671–686.
   PubMed Web of Science ®Google Scholar
• Emens LA, Cruz C, Eder JP, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol. 2019;5:74–82.
   PubMed Web of Science ®Google Scholar
• Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 Study. J Clin Oncol. 2016;34:2460–2467.
   PubMed Web of Science ®Google Scholar
• Emens LA, Adams S, Barrios CH, et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: iMpassion130 final overall survival analysis. Ann Oncol. 2021;32:983–993.
   PubMed Web of Science ®Google Scholar
• Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396:1817–1828.
   PubMed Web of Science ®Google Scholar
• Cortes J, Cescon DW, Rugo HS, et al. Abstract GS3-01: additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer. Cancer Res. 2021;81:GS3–01.
   Google Scholar
• Merck. Merck announces phase 3 KEYNOTE-355 trial met primary endpoint of overall survival (OS) in patients with metastatic triple-negative breast cancer whose tumors expressed PD-L1 ( CPS =10). Merck [cited 2022 Dec 22]. https://www.merck.com/news/merck-announces-phase-3-keynote-355-trial-met-primary-endpoint-of-overall-survival-os-in-patients-with-metastatic-triple-negative-breast-cancer-whose-tumors-expressed-pd-l1-cps=10/(2021)
   Google Scholar
• Rugo HS, Loi S, Adams S, et al. LBA20-Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): post-hoc analysis of IMpassion130. Ann Oncol. 2019;30:v858–9.
   PubMed Web of Science ®Google Scholar
• Ribas A, Hu-Lieskovan S. What does PD-L1 positive or negative mean? J Exp Med. 2016;213:2835–2840.
   PubMed Web of Science ®Google Scholar
• Miles D, Gligorov J, André F, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/ metastatic triple-negative breast cancer. Ann Oncol. 2021;32:994–1004.
   PubMed Web of Science ®Google Scholar
• Roche. Roche provides update on Tecentriq US indication for PD-L1-positive, metastatic triple-negative breast cancer. 2021. https://www.roche.com/media/releases/med-cor-2021-08-27.htm
   Google Scholar
• Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810–821.
   PubMed Web of Science ®Google Scholar
• Schmid P, Cortés J, Dent R, et al. LBA8_PR - KEYNOTE-522: phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple- negative breast cancer (TNBC). Ann Oncol. 2019;30:v853–4.
   PubMedGoogle Scholar
• Gianni L, Huang CS, Egle D, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: neoTRIP Michelangelo randomized study. Ann Oncol. 2022 May;33(5):534–543.
   PubMed Web of Science ®Google Scholar
• Voorwerk L, Slagter M, Horlings HM, et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat Med. 2019;25:920–928.
   PubMed Web of Science ®Google Scholar
• Brown JS, Sundar R, Lopez J. Combining DNA damaging therapeutics with immunotherapy: more haste, less speed. Br J Cancer. 2018;118:312–324.
   PubMed Web of Science ®Google Scholar
• Gopalakrishnan V, Helmink BA, Spencer CN, et al. The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy. Cancer Cell. 2018;33:570–580.
   PubMed Web of Science ®Google Scholar
• Barroso-Sousa R, Keenan TE, Pernas S, et al. Tumor mutational burden and PTEN alterations as molecular correlates of response to PD-1/L1 blockade in metastatic triple- negative breast cancer. Clin Cancer Res. 2020;26:2565–2572.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Humeau J, Buqué A, et al. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020;17:725–741.
   PubMed Web of Science ®Google Scholar
• Petroni G, Buqué A, Zitvogel L, et al. Immunomodulation by targeted anticancer agents. Cancer Cell. 2021;39:310–345.
   PubMed Web of Science ®Google Scholar
• Schmid P, Im SA, Armstrong A, et al. BEGONIA: phase 1b/2 study of durvalumab (D) combinations in locally advanced/ metastatic triple-negative breast cancer (TNBC) — initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd). J Clin Oncol. 2021;39:1023.
   Web of Science ®Google Scholar
• Han H, Alemany CA, Brown-Glaberman UA, et al. Abstract PD1-06: open label phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer. Cancer Res. 2020;80:1–6.
   Web of Science ®Google Scholar
• Schmid P, Jung KH, Wysocki PJ, et al. Datopotamab deruxtecan + durvalumab as first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer: initial results from BEGONIA, a phase 1b/2 study. ESMO Breast Cancer Congress. Annals of Oncology. 2022;33(suppl_3):S194–S223.
   Google Scholar
• Schmid P, Loirat D, Savas P, et al. Abstract CT049: phase Ib study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (TNBC). Cancer Res. 2019;79:CT049.
   Web of Science ®Google Scholar
• Brufsky A, Kim SB, Zvirbule Ž, et al. A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis. Ann Oncol. 2021;32:652–660.
   PubMed Web of Science ®Google Scholar
• Messenheimer DJ, Jensen SM, Afentoulis ME, et al. Timing of PD-1 blockade is critical to effective combination immunotherapy with anti-OX40. Clin. Cancer Res. 2017;23:6165–6177.
   Web of Science ®Google Scholar
• Coats S, Williams M, Kebble B, et al. Antibody-drug conjugates: future directions in clinical and translational strategies to improve the therapeutic index. Clin Cancer Res. 2019;25:5441–5448.
   PubMed Web of Science ®Google Scholar
• Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18:327–344.
   PubMed Web of Science ®Google Scholar
• Trerotola M, Cantanelli P, Guerra E, et al. Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene. 2013;32:222–233.
   PubMed Web of Science ®Google Scholar
• Huang H, Groth J, Sossey-Alaoui K, et al. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors. Clin Cancer Res. 2005;11:4357–4364.
   PubMed Web of Science ®Google Scholar
• Sharkey RM, McBride WJ, Cardillo TM, et al. Enhanced delivery of SN-38 to human tumor xenografts with an anti-trop-2-SN-38 antibody conjugate (Sacituzumab Govitecan). Clin Cancer Res. 2015;21:5131–5138.
   PubMed Web of Science ®Google Scholar
• Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019;380:741–751.
   PubMed Web of Science ®Google Scholar
• Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529–1541.
   PubMed Web of Science ®Google Scholar
• Immunomedics announces ASCENT study to be stopped for compelling efficacy [news release]. Morris Plains, New York, Immunomedics 2020 Apr 6.
   Google Scholar
• Cardillo TM, Sharkey RM, Rossi DL, et al. Synthetic lethality exploitation by an anti-trop-2-SN-38 antibody-drug conjugate, IMMU-132, plus PARP inhibitors in BRCA1/2-wild- type triple-negative breast cancer. Clin Cancer Res. 2017;23:3405–3415.
   PubMed Web of Science ®Google Scholar
• Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382:610–621.
   PubMed Web of Science ®Google Scholar
• Modi S, Jacot W, Yamashita T, et al. DESTINY-Breast04 trial investigators. trastuzumab deruxtecan in previously treated her2-low advanced breast cancer. N Engl J Med. 2022 Jul 7;3871 9–20.
   PubMed Web of Science ®Google Scholar
• Michmerhuizen AR, Spratt DE, Pierce LJ, et al. ARe we there yet? Understanding androgen receptor signaling in breast cancer. NPJ Breast Cancer. 2020;6:47.
   PubMed Web of Science ®Google Scholar
• Kono M, Fujii T, Lim B, et al. Androgen receptor function and androgen receptor-targeted therapies in breast cancer: a review. JAMA Oncol. 2017;3:1266–1273.
   PubMed Web of Science ®Google Scholar
• Masuda H, Baggerly Keith A, Wang Y, et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013;19(19):5533–5540.
   PubMed Web of Science ®Google Scholar
• Basile D, Cinausero M, Iacono D, et al. Androgen receptor in estrogen receptor positive breast cancer: beyond expression. Cancer Treat Rev. 2017;61:15–22.
   PubMed Web of Science ®Google Scholar
• Traina TA, Miller K, Yardley DA, et al. Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer. J Clin Oncol. 2018;36:884–890.
   PubMed Web of Science ®Google Scholar
• Gucalp A, Tolaney S, Isakoff SJ, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res. 2013;19:5505–5512.
   PubMed Web of Science ®Google Scholar
• Bonnefoi H, Grellety T, Tredan O, et al. A phase II trial of Abiraterone acetate plus prednisone in patients with triple- negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). Ann Oncol. 2016;27:812–818.
   PubMed Web of Science ®Google Scholar
• Vasan N, Toska E, Scaltriti M. Overview of the relevance of PI3K pathway in HR-positive breast cancer. Ann Oncol. 2019;30:x3–x11.
   PubMed Web of Science ®Google Scholar
• Gordon MA, D’Amato NC, Gu H, et al. Synergy between androgen receptor antagonism and inhibition of mTOR and HER2 in breast cancer. Mol Cancer Ther. 2017;16:1389–1400.
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Abramson VG, Sanders ME, et al. TBCRC 032 IB/II multicenter study: molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR+ metastatic triple-negative breast cancer. Clin Cancer Res. 2020;26:2111–2123.
   PubMed Web of Science ®Google Scholar
• Asghar US, Barr AR, Cutts R, et al. Single-cell dynamics determines response to CDK4/6 inhibition in triple-negative breast cancer. Clin Cancer Res. 2017;23:5561–5572.
   PubMed Web of Science ®Google Scholar
• Marra A, Curigliano G. Are all cyclin-dependent kinases 4/6 inhibitors created equal? NPJ Breast Cancer. 2019;5:27.
   PubMed Web of Science ®Google Scholar
• Gucalp A, Boyle LA, Alano T, et al. Phase II trial of bicalutamide in combination with palbociclib for the treatment of androgen receptor+ metastatic breast cancer. J Clin Oncol. 2020;38:1017.
   Web of Science ®Google Scholar
• O’Neil NJ, Bailey ML, Hieter P. Synthetic lethality and cancer. Nat Rev Genet. 2017;18:613–623.
   PubMed Web of Science ®Google Scholar
• Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917–921.
   PubMed Web of Science ®Google Scholar
• Tung N, Arun B, Hacker MR, et al. TBCRC 031: randomized phase II study of neoadjuvant cisplatin versus doxorubicin-cyclophosphamide in germline BRCA carriers with HER2- negative breast cancer (the INFORM trial). J Clin Oncol. 2020 May 10;38(14):1539–1548.
   Web of Science ®Google Scholar
• Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523–533.
   PubMed Web of Science ®Google Scholar
• Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753–763.
   PubMed Web of Science ®Google Scholar
• Robson ME, Tung N, Conte P, et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019;30:558–566.
   PubMed Web of Science ®Google Scholar
• Loibl S, O’Shaughnessy J, Untch M, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carbo- platin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018;19:497–509.
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy J, Schwartzberg L, Danso MA, et al. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol. 2014;32:3840–3847.
   PubMed Web of Science ®Google Scholar
• Rugo HS, Olopade OI, DeMichele A, et al. Adaptive randomization of veliparib-carboplatin treatment in breast cancer. N Engl J Med. 2016;375:23–34.
   PubMed Web of Science ®Google Scholar
• Fasching PA, Link T, Hauke J, et al. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). Ann Oncol. 2021;32:49–57.
   PubMed Web of Science ®Google Scholar
• Lee JM, Cimino-Mathews A, Peer CJ, et al. Safety and clinical activity of the programmed death-ligand 1 inhibitor durvalumab in combination with poly (ADP-Ribose) polymerase inhibitor olaparib or vascular endothelial growth factor receptor 1-3 inhibitor cediranib in women’s cancers: a dose-escalation, phase I study. J Clin Oncol. 2017;35:2193–2202.
   PubMed Web of Science ®Google Scholar
• Vinayak S, Tolaney SM, Schwartzberg L, et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol. 2019;5:1132–1140.
   PubMed Web of Science ®Google Scholar
• Jiao S, Xia W, Yamaguchi H, et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer- associated immunosuppression. Clin Cancer Res. 2017;23:3711–3720.
   PubMed Web of Science ®Google Scholar
• Sato H, Niimi A, Yasuhara T, et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat Commun. 2017;8:1751.
   PubMed Web of Science ®Google Scholar
• D’Andrea AD. Mechanisms of PARP inhibitor sensitivity and resistance. DNA Repair (Amst). 2018;71:172–176.
   PubMed Web of Science ®Google Scholar
• Norquist B, Wurz KA, Pennil CC, et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol. 2011;29:3008–3015.
   PubMed Web of Science ®Google Scholar
• Barber LJ, Sandhu S, Chen L, et al. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J Pathol. 2013;229:422–429.
   PubMed Web of Science ®Google Scholar
• Waks AG, Cohen O, Kochupurakkal B, et al. Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer. Ann Oncol. 2020;31:590–598.
   PubMed Web of Science ®Google Scholar
• Ray Chaudhuri A, Callen E, Ding X, et al. Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature. 2016;535:382–387.
   PubMed Web of Science ®Google Scholar
• Sonnenblick A, de Azambuja E, HA A Jr, et al. An update on PARP inhibitors–moving to the adjuvant setting. Nat Rev Clin Oncol. 2015;12:27–41.
   PubMed Web of Science ®Google Scholar
• Pettitt SJ, Krastev DB, Brandsma I, et al. Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance. Nat Commun. 2018;9:1849.
   PubMed Web of Science ®Google Scholar
• Xu G, Chapman JR, Brandsma I, et al. REV7 counteracts DNA double-strand break resection and affects PARP inhibition. Nature. 2015;521:541–544.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70.
   PubMed Web of Science ®Google Scholar
• Duncan JS, Whittle MC, Nakamura K, et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell. 2012;149:307–321.
   PubMed Web of Science ®Google Scholar
• Di Leo A, Gomez HL, Aziz Z, et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol. 2008;26:5544–5552.
   PubMed Web of Science ®Google Scholar
• Finn RS, Press MF, Dering J, et al. Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer. J Clin Oncol. 2009;27:3908–3915.
   PubMed Web of Science ®Google Scholar
• Baselga J, Gómez P, Greil R, et al. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol. 2013;31:2586–2592.
   PubMed Web of Science ®Google Scholar
• Nabholtz JM, Chalabi N, Radosevic-Robin N, et al. Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer. Int J Cancer. 2016;138:2274–2280.
   PubMed Web of Science ®Google Scholar
• Ali R, Wendt MK. The paradoxical functions of EGFR during breast cancer progression. Signal Transduct Target Ther. 2017;2:1–7.
   Web of Science ®Google Scholar
• Schmid P, Forster MD, Summers YJ, et al. A study of vistusertib in combination with selumetinib in patients with advanced cancers: TORCMEK phase Ib results. J Clin Oncol. 2017;35:2548.
   Web of Science ®Google Scholar
• Subbiah V, Puzanov I, Blay JY, et al. Pan-cancer efficacy of vemurafenib in BRAFV600-mutant non- melanoma cancers. Cancer Discov. 2020;10:657–663.
   PubMed Web of Science ®Google Scholar
• Jiang YZ, Ma D, Suo C, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell. 2019;35:428–440.
   PubMed Web of Science ®Google Scholar
• Dent R, Kim SB, Oliveira M, et al. Abstract GS3-04: double-blind placebo (PBO)-controlled randomized phase III trial evaluating first-line ipatasertib (IPAT) combined with paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer (aTNBC): primary results from IPATunity130 Cohort A. Cancer Res. 2021;81:GS3–04.
   Web of Science ®Google Scholar
• Pascual J, Turner NC. Targeting the PI3-kinase pathway in triple-negative breast cancer. Ann Oncol. 2019;30(7):1051–1060.
   PubMed Web of Science ®Google Scholar
• Mosele F, Stefanovska B, Lusque A, et al. Outcome and molecular landscape of patients with PIK3CA- mutated metastatic breast cancer. Ann Oncol. 2020;31:377–386.
   PubMed Web of Science ®Google Scholar
• Davies BR, Greenwood H, Dudley P, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther. 2012;11:873–887.
   PubMed Web of Science ®Google Scholar
• Sharma P, Abramson VG, O’Dea A, et al. Clinical and biomarker results from phase I/II study of PI3K inhibitor BYL 719 (alpelisib) plus nab-paclitaxel in HER2-negative metastatic breast cancer. J Clin Oncol. 2018;36:1018.
   Google Scholar
• Kim SB, Dent R, Im SA, et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo- controlled, phase 2 trial. Lancet Oncol. 2017;18:1360–1372.
   PubMed Web of Science ®Google Scholar
• Schmid P, Abraham J, Chan S, et al. Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial. J Clin Oncol. 2020;38:423–433.
   PubMed Web of Science ®Google Scholar
• Dent R, Trudeau M, Pritchard KI, et al. Triple-Negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007 Aug;13(15):4429–4434.
   PubMed Web of Science ®Google Scholar